Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 diabetes

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Jin, Ling ^a   Tu, Jian ^a,b   Jia, Jianwei ^a   An, Wenbin ^b   Tan, Huanran ^a   Cui, Qinghua ^a   Li, Zhixin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Beijing Jishuitan Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTISINE; TROLOX C; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID; ALKALOID; AZOCINE DERIVATIVE; CHROMAN DERIVATIVE; QUINOLIZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG REPOSITIONING; DRUG RESPONSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SCORING SYSTEM; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; INSTITUTE FOR CANCER RESEARCH MOUSE;

ALKALOIDS; ANIMALS; AZOCINES; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; MALE; MICE; MICE, INBRED ICR; QUINOLIZINES;

EID: 84902075817     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-153     Document Type: Article

References (22)

1. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011, 12:303-311. 10.1093/bib/bbr013, 3137933, 21690101.
2. Swamidass SJ. Mining small-molecule screens to repurpose drugs. Brief Bioinform 2011, 12:327-335. 10.1093/bib/bbr028, 21715466.
3. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature 2009, 462:175-181. 10.1038/nature08506, 2784146, 19881490.
4. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008, 321:263-266. 10.1126/science.1158140, 18621671.
5. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935. 10.1126/science.1132939, 17008526.
6. Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS One 2009, 4:e4346. 10.1371/journal.pone.0004346, 2631151, 19194489.
7. Carrella D, Napolitano F, Rispoli R, Miglietta M, Carissimo A, Cutillo L, Sirci F, Gregoretti F, Di Bernardo D. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis. Bioinformatics 2014, [Epub ahead of print].
8. Tan F, Yang R, Xu X, Chen X, Wang Y, Ma H, Liu X, Wu X, Chen Y, Liu L, Jia X. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity. Mol Biosyst 2014, 10:1126-1138. 10.1039/c3mb70554d, 24603772.
9. Rung J, Brazma A. Reuse of public genome-wide gene expression data. Nat Rev Genet 2012, 14:89-99. 10.1038/nrg3394, 23269463.
10. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011, 3:96ra77. 3502016, 21849665.
11. Liu Y, Hu B, Fu C, Chen X. DCDB: drug combination database. Bioinformatics 2009, 26:587-588.
12. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A 2012, 110:E170-179. 3545813, 23251029.
13. Zhao J, Zhang XS, Zhang S. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. CPT Pharmacometrics Syst Pharmacol 2014, 3:e102. 10.1038/psp.2013.79, 3944117, 24573337.
14. Chen X, Ren B, Chen M, Liu MX, Ren W, Wang QX, Zhang LX, Yan GY. ASDCD: antifungal synergistic drug combination database. PLoS One 2014, 9:e86499. 10.1371/journal.pone.0086499, 3901703, 24475134.
15. Wendy L, Bennett NMM, Sonal S, Segal JB, Wilson LM, Ranee C, Marinopoulos SS, Puhan MA, Padmini R, Lauren B, Nicholson WK, Susan H, Bass EB, Shari B. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:12. 10.7326/0003-4819-154-1-201101040-00003, 21200034.
16. Mickle DA, Weisel RD. Future directions of vitamin E and its analogues in minimizing myocardial ischemia-reperfusion injury. Can J Cardiol 1993, 9:89-93.
17. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786. 10.1016/S0140-6736(96)90866-1, 8622332.
18. Knockaert L, Berson A, Ribault C, Prost PE, Fautrel A, Pajaud J, Lepage S, Lucas-Clerc C, Begue JM, Fromenty B, Robin MA. Carbon tetrachloride-mediated lipid peroxidation induces early mitochondrial alterations in mouse liver. Lab Invest 2011, 92:396-410.
19. Desaphy JF, Pierno S, Liantonio A, Giannuzzi V, Digennaro C, Dinardo MM, Camerino GM, Ricciuti P, Brocca L, Pellegrino MA, Bottinelli R, Camerino DC. Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles. Pharmacol Res 2010, 61:553-563. 10.1016/j.phrs.2010.01.012, 20116431.
20. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006, 15:280-285. 10.1136/tc.2005.015487, 2563611, 16885576.
21. Marks MJ, Whiteaker P, Collins AC. Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. Mol Pharmacol 2006, 70:947-959. 10.1124/mol.106.025338, 16728647.
22. Li J, Lenferink AE, Deng Y, Collins C, Cui Q, Purisima EO, O'Connor-McCourt MD, Wang E. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun 2010, 1:34. 2972666, 20975711.